Chiroscience Appoints Head of Investor Relations and Corporate Communications.LONDON--(BUSINESS WIRE)--February 8, 1999--Chiroscience Group plc today announced the appointment of Mr. David Dible as Head of Investor Relations Investor relations The process by which the corporation communicates with its investors. and Corporate Communications Corporate communications is the process of facilitating information and knowledge exchanges with internal and key external groups and individuals that have a direct relationship with an enterprise. with effect from March 1, 1999. He will report directly to Dr. John Padfield, Chief Executive. Mr. Dible is a biological scientist who has a broad range of experience in healthcare, equity research and, most recently, business development and investor relations. He has worked in the UK with Wood Mackenzie, Edinburgh Fund Managers, Baring Securities and SG Warburg Securities, in Japan with Hoare Govett, and in Sweden with Arjo AB. David's most recent role was as Investor Relations Manager for Scotia Holdings PLC. Dr. John Padfield, Chief Executive Officer of Chiroscience Group plc, commented : "I am delighted that we have been able to appoint an individual with the very broad range of experience that David has developed. He will work closely with myself and other members of the Board to continue to communicate to all external audiences the important progress that the Group will make as we seek to build Europe's premier emerging pharmaceutical company." Chiroscience Group plc Chiroscience is an emerging pharmaceutical company which uses its diverse technology platform to discover, develop and bring to market novel medicines for improved healthcare. It has three businesses: Chiroscience R&D, Rapigene and ChiroTech. Chiroscience R&D's focus is on innovative small molecule drugs and related diagnostics in the therapeutic areas of inflammatory disease, pain, osteoporosis, cancer and autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause . Its technology platform allows the conception and development of receptor-based and enzyme-inhibiting small molecule drugs with high selectivity of action. Rapigene is involved in the creation and provision of genomic technologies and services to partner companies and to Chiroscience's drug discovery programs. Its DNA analysis DNA analysis Any technique used to analyze genes and DNA. See Chromosome walking, DNA fingerprinting, Footprinting, In situ hybridization, Jeffries' probe, Jumping libraries, PCR, RFLP analysis, Southern blot hybridization. systems comprise of DNA hybridization DNA hybridization Molecular medicine A technique for determining the presence of a target DNA in a sample of tissue or cells. See HLA analysis, Paternity testing, RFLP analysis. , DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. arrays and mass spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. tags. ChiroTech provides chiral chi·ral adj. Of or relating to the structural characteristic of a molecule that makes it impossible to superimpose it on its mirror image. chi·ral technology services to pharmaceutical and related industries, including Chiroscience R&D. Chiroscience Group plc is listed on the London Stock Exchange London Stock Exchange London marketplace for securities. It was formed in 1773 by a group of stockbrokers who had been doing business informally in local coffeehouses. and is based in Cambridge and Stevenage, UK, and Seattle, Washington, USA.
Chiroscience financial highlights for the six months to August
31, 1998 (unaudited):
-- Revenues increased to (pound)11.4m (H1 1997: (pound)9.2m); net
loss for the period (pound)11.4m (H1 1997: (pound)14.4m)
-- ChiroTech contributed sales of (pound)6.8m (H1 1997:
(pound)5.9m); Chiroscience's drug discovery business contributed
revenues of (pound)4.5m (H1 1997: (pound)3.3m).
-- Investment in research and development of (pound)13.5m (1H 1997:
(pound)19.0m).
-- Current cash reserves of (pound)59m as at September 24, 1998.
Additional information on Chiroscience can be accessed on the company's home page: http://www.chiroscience.com. |
|
|||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion